Hepatitis B vaccination in acute lymphoblastic leukemia.
Active immunization against hepatitis B virus infection was carried out in 162 patients with acute lymphoblastic leukemia attending the Outpatient Department at Tata Memorial Hospital. Recombinant DNA vaccine was given in three doses at 0, 1 and 2 months followed by a booster 1 year after the first dose. Antibodies to hepatitis B surface antigen could be detected in 19.7% of patients following vaccination. Of these only 10.5% had titers in the protective range. Immunosuppression induced by both disease and treatment appears to diminish responsiveness to vaccination. Passive active prophylaxis with both vaccine and immunoglobulin may be a more effective alternative in these patients.
Goyal
S
S
Department of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai, India.
Pai
S K
SK
Kelkar
R
R
Advani
S H
SH
D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000097:blood / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D006509:Hepatitis B / Q000209:etiology / Q000276:immunology* / Q000517:prevention & control*; D017325:Hepatitis B Vaccines / Q000008:administration & dosage / Q000276:immunology*; D006801:Humans; D007165:Immunosuppression Therapy; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood / Q000150:complications / Q000276:immunology*; D014611:Vaccination; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000276:immunology
D000914:Antibodies, Viral; D017325:Hepatitis B Vaccines; D019444:Vaccines, DNA